Profiling EGFR Kinase Inhibitor Resistance Pathways in Non-Small Lung Cancer Cells

机译：在非小肺癌细胞中的谱分析EGFR激酶抑制剂抵抗途径

获取原文

页面导航

摘要
著录项
相似文献
相关主题

摘要

TMT labeling enables the simultaneous quantification of protein expression from multiple experimental conditions when coupled with the high resolution/accurate mass of the Orbitrap instruments. High pH reversed-phase fractionation of unenriched and phospho-peptide enriched samples resulted in over 7,800 protein groups identified and over 5,500 proteins quantified from ten different experimental conditions. Protein expression ratios from TMT ion reporters correlated well with previous SILAC studies and western blot analysis. Cluster analysis revealed differences in regulation of key ErbB pathway signaling proteins.

机译：TMT标记能够在与高分辨率/精确的轨道仪器的高分辨率/精确质量相结合时同时定量来自多个实验条件的蛋白质表达。未成分和磷酸肽富集样品的高pH反相分级导致鉴定出7,800种蛋白质基团，并从10种不同的实验条件中量化超过5,500种蛋白质。 TMT离子报告器的蛋白质表达率与先前的氧化铝研究和Western印迹分析相关。聚类分析显示了关键ERBB途径信号蛋白调节的差异。

著录项

来源
《ASMS Conference on Mass Spectrometry and Allied Topics》|2014年||共1页
会议地点
作者
Ryan D. Bomgarden; Ryan Jacobs; Jason Fong; David Moravec; Gregory M. Botting; Neelu Puri; Rosa Viner; Michael Blank; John C. Rogers;
展开▼
作者单位

展开▼
会议组织
原文格式 PDF
正文语种
中图分类 TB994.5-53;
关键词

相似文献

外文文献
中文文献
专利

1. 第一代EGFR酪氨酸激酶抑制剂治疗106例复合EGFR突变肺癌患者:一项单中心临床研究 [J] . Xiangyang Yu, Xuewen Zhang, Zichen Zhang, 癌症（英文版） . 2019,第010期
2. Genotypic and histological evolution of non-small cell lung cancers (NSCLC) with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) [évolution histologique et génotypique des cancers bronchiques non à petites cellules (CBNPC) avec résistance acquise sous TKI EGFR] [J] . WislezM. Bulletin du Cancer: Journal de l'Association Francaise pour l'Etude du Cancer . 2011,第12期

机译：对表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）获得性耐药的非小细胞肺癌（NSCLC）的基因型和组织学演变EGFR]
3. The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer. [J] . Kono SA, Marshall ME, Ware KE, Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy . 2009,第4a5期

机译：在非小细胞肺癌中，成纤维细胞生长因子受体信号转导通路作为对EGFR特异性酪氨酸激酶抑制剂内在抗性的介体。
4. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. [J] . Thomson S, Petti F, Sujka-Kwok I, Clinical and experimental metastasis . 2008,第8期

机译：间充质样非小细胞肺癌细胞系中的激酶转换通过途径冗余有助于EGFR抑制剂耐药。
5. Profiling EGFR Kinase Inhibitor Resistance Pathways in Non-Small Lung Cancer Cells [C] . Ryan D. Bomgarden, Ryan Jacobs, Jason Fong, ASMS Conference on Mass Spectrometry and Allied Topics . 2014

机译：在非小肺癌细胞中的谱分析EGFR激酶抑制剂抵抗途径
6. Pharmacology Profiles of ALK and FLT3 Kinase Inhibitors against Non-Small-Cell Lung Cancer Cells and Acute Myeloid Leukemia Cells with Cancer Driver Mutations [D] . 森政道 2019

机译：ALK和FLT3激酶抑制剂对非小细胞肺癌细胞和急性髓系白血病细胞的癌症驱动突变的药理作用
7. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients [O] . Ryo Ko, Hirotsugu Kenmotsu, Masakuni Serizawa, 2016

机译：来自非小细胞肺癌的EGFR T790M突变频率和多活检样本在日本患者中对EGFR酪氨酸激酶抑制剂产生了获得性耐药
8. Frequency of T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients [O] . 2016

机译：来自非小细胞肺癌的T790M突变的频率和多活检样本在日本患者中对EGFR酪氨酸激酶抑制剂产生了获得性耐药

Profiling EGFR Kinase Inhibitor Resistance Pathways in Non-Small Lung Cancer Cells

摘要

著录项

相似文献

相关主题

期刊订阅